JAK2V617F mutation in a patient with B-cell chronic lymphocytic leukemia and prefibrotic primary myelofibrosis
| Autor: | Milica Radojkovic, Vesna Spasovski, Vesna Cemerikic-Martinovic, Slobodan Ristic, Tatjana Kostic, Sonja Pavlovic |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Male
Chronic lymphocytic leukemia Cell Purine analogue lcsh:Medicine myelofibrosis medicine.disease_cause 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases Medicine Humans 030212 general & internal medicine Myelofibrosis Aged CD20 Mutation Janus kinase 2 biology business.industry lcsh:R Hematopoietic stem cell General Medicine Janus Kinase 2 medicine.disease Leukemia Lymphocytic Chronic B-Cell 3. Good health JAK2V617F mutation medicine.anatomical_structure Primary Myelofibrosis 030220 oncology & carcinogenesis Immunology biology.protein chronic lymphocytic leukemia business |
| Zdroj: | Srpski Arhiv za Celokupno Lekarstvo, Vol 143, Iss 11-12, Pp 739-743 (2015) Srpski arhiv za celokupno lekarstvo (2015) 143(11-12):739-743 |
| ISSN: | 2406-0895 0370-8179 |
| Popis: | Introduction. Secondary malignancies, particularly solid tumors, are common in patients with chronic lymphocytic leukemia (CLL), but association of myeloproliferative neoplasms and chronic lymphocytic leukemia in the same patient is very rare. Case Outline. We report of a 67-year-old man with B-cell chronic lymphoid leukemia (B-CLL) who developed primary myelofibrosis (PMF) nine years after initial diagnosis. Patient received alkylation agents and purine analogue, which can be a predisposing factor for the development of myeloproliferative neoplasms. JAK2V617F mutation was not present initially at the time of CLL diagnosis, but was found after nine years when PMF occurred, which indicates that B-CLL and PMF represent two separate clonal origin neoplasms. Conclusion. Pathogenic mechanisms for the development of myeloproliferative and lymphoproliferative neoplasms in the same patient are unknown. Further research is needed to determine whether these malignancies originate from two different cell clones or arise from the same pluripotent hematopoietic stem cell. [Projekat Ministarstva nauke Republike Srbije, br. III 41004] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|